$9.54 Billion is the total value of Baker Brothers Advisors's 135 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 15.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INCY | Buy | Incyte Corporation | $1,879,426,000 | +10.4% | 23,498,697 | +0.0% | 19.70% | +9.7% |
| SGEN | Buy | Seattle Genetics, Inc. | $1,747,287,000 | +15.2% | 43,238,967 | +0.0% | 18.32% | +14.5% |
| ABBV | AbbVie Inc. | $889,866,000 | +8.4% | 14,373,538 | 0.0% | 9.33% | +7.7% | |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $795,813,000 | +17.5% | 24,516,738 | +1.3% | 8.34% | +16.9% |
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $763,995,000 | -16.1% | 6,543,295 | +0.0% | 8.01% | -16.6% |
| Incyte Corporation Notes 1.25% 11/15/2020 144Anote 1.25% 11/15/2020 | $467,293,000 | +8.1% | 274,500,000 | 0.0% | 4.90% | +7.5% | ||
| Incyte Corporation Notes 0.375% 11/15/2018 144Anote 0.375% 11/15/2018 | $431,835,000 | +8.5% | 259,000,000 | 0.0% | 4.53% | +7.9% | ||
| BMRN | BioMarin Pharmaceutical Inc. | $373,944,000 | -5.7% | 4,806,483 | 0.0% | 3.92% | -6.2% | |
| GHDX | Buy | Genomic Health, Inc. | $353,955,000 | +4.6% | 13,668,866 | +0.1% | 3.71% | +4.0% |
| DBVT | DBV Technologies S.A.sponsored adr | $179,722,000 | +0.2% | 5,509,560 | 0.0% | 1.88% | -0.4% | |
| XenoPort, Inc. Notes 2.5% 2/1/2022note 2.5% 2/1/2022 | $98,471,000 | +34.1% | 100,000,000 | 0.0% | 1.03% | +33.3% | ||
| ACOR | Acorda Therapeutics, Inc. | $93,376,000 | -3.6% | 3,661,082 | 0.0% | 0.98% | -4.1% | |
| BioMarin Pharmaceutical Inc. Notes 1.875% 4/23/2017note 1.875% 4/23/2017 | $84,908,000 | -5.5% | 22,379,000 | 0.0% | 0.89% | -6.0% | ||
| CERS | Cerus Corporation | $84,572,000 | +5.2% | 13,553,275 | 0.0% | 0.89% | +4.6% | |
| ONCE | Buy | Spark Therapeutics, Inc. | $67,407,000 | +80.9% | 1,318,341 | +4.4% | 0.71% | +79.9% |
| Acorda Therapeutics, Inc. Notes 1.75% 6/15/2021note 1.75% 6/15/2021 | $67,351,000 | -1.6% | 77,083,000 | 0.0% | 0.71% | -2.2% | ||
| BLCM | Bellicum Pharmaceuticals, Inc. | $63,059,000 | +38.6% | 4,865,647 | 0.0% | 0.66% | +37.7% | |
| BGNE | BeiGene, Ltd.sponsored adr | $56,998,000 | +1.7% | 1,912,680 | 0.0% | 0.60% | +1.2% | |
| HRTX | Sell | Heron Therapeutics, Inc. | $51,573,000 | -6.6% | 2,857,250 | -1.7% | 0.54% | -7.0% |
| AQXP | Aquinox Pharmaceuticals, Inc. | $51,321,000 | -24.9% | 7,752,487 | 0.0% | 0.54% | -25.4% | |
| Sell | Clovis Oncology, Inc. 2.5% 9/15/2021note 2.5% 9/15/2021 | $51,310,000 | -41.6% | 72,758,000 | -43.7% | 0.54% | -41.9% | |
| NVTA | Invitae Corporation | $48,441,000 | -27.8% | 6,554,967 | 0.0% | 0.51% | -28.1% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $42,630,000 | +0.4% | 15,010,534 | 0.0% | 0.45% | -0.2% | |
| NBIX | Neurocrine Biosciences, Inc. | $40,697,000 | +14.9% | 895,422 | 0.0% | 0.43% | +14.5% | |
| VSAR | Sell | Versartis, Inc. | $30,121,000 | +17.4% | 2,723,399 | -14.9% | 0.32% | +16.6% |
| Exelixis, Inc. Notes 4.25% 8/15/2019note 4.25% 8/15/2019 | $29,654,000 | +50.0% | 20,000,000 | 0.0% | 0.31% | +48.8% | ||
| AAAP | Buy | Advanced Accelerator Applications S.A.sponsored adr | $25,188,000 | +16.9% | 833,089 | +35.5% | 0.26% | +16.3% |
| XNPT | XenoPort, Inc. | $24,469,000 | +56.1% | 3,475,672 | 0.0% | 0.26% | +55.8% | |
| ITCI | Intra-Cellular Therapies, Inc. | $23,648,000 | +39.6% | 609,166 | 0.0% | 0.25% | +38.5% | |
| SGMO | Sangamo BioSciences, Inc. | $23,484,000 | -4.3% | 4,055,876 | 0.0% | 0.25% | -5.0% | |
| NTLA | New | Intellia Therapeutics, Inc. | $22,676,000 | – | 1,062,120 | +100.0% | 0.24% | – |
| EXEL | Exelixis, Inc. | $20,150,000 | +95.3% | 2,580,000 | 0.0% | 0.21% | +93.6% | |
| MDVN | Medivation, Inc. | $19,892,000 | +31.1% | 329,876 | 0.0% | 0.21% | +30.6% | |
| ACHN | Achillion Pharmaceuticals, Inc. | $19,309,000 | +1.0% | 2,475,515 | 0.0% | 0.20% | 0.0% | |
| NVAX | Novavax, Inc. | $17,297,000 | +40.9% | 2,379,254 | 0.0% | 0.18% | +40.3% | |
| PGNX | Sell | Progenics Pharmaceuticals, Inc. | $16,754,000 | -11.7% | 3,970,250 | -8.7% | 0.18% | -12.0% |
| XNCR | Xencor, Inc. | $16,561,000 | +41.5% | 872,072 | 0.0% | 0.17% | +41.5% | |
| HALO | Sell | Halozyme Therapeutics, Inc. | $15,862,000 | -13.3% | 1,838,057 | -4.8% | 0.17% | -14.0% |
| ARRY | Array BioPharma Inc. | $15,346,000 | +20.7% | 4,310,666 | 0.0% | 0.16% | +20.1% | |
| Corsicanto Ltd. 3.5% 1/15/2032note 3.5% 1/15/2032 | $15,285,000 | +26.3% | 15,000,000 | 0.0% | 0.16% | +25.0% | ||
| Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019note 2.0% 8/15/2019 | $14,840,000 | +9.7% | 26,517,000 | 0.0% | 0.16% | +9.1% | ||
| DSCI | Derma Sciences, Inc. | $14,784,000 | +27.1% | 3,752,390 | 0.0% | 0.16% | +26.0% | |
| INSM | Insmed Incorporated | $14,790,000 | -22.2% | 1,500,000 | 0.0% | 0.16% | -22.5% | |
| GLPG | Sell | Galapagos NVsponsored adr | $14,416,000 | +13.6% | 259,894 | -14.3% | 0.15% | +12.7% |
| FOMX | Foamix Pharmaceuticals Ltd. | $14,235,000 | -2.6% | 2,241,702 | 0.0% | 0.15% | -3.2% | |
| BioMarin Pharmaceutical Inc. Notes 0.75% 10/15/2018note 0.75% 10/15/2018 | $13,573,000 | -3.9% | 12,228,000 | 0.0% | 0.14% | -4.7% | ||
| BLUE | Sell | bluebird bio, Inc. | $12,725,000 | -15.2% | 293,943 | -16.7% | 0.13% | -15.8% |
| MRTX | Sell | Mirati Therapeutics, Inc. | $12,390,000 | -82.3% | 2,269,198 | -30.6% | 0.13% | -82.4% |
| TGTX | TG Therapeutics, Inc. | $12,144,000 | -28.9% | 2,003,991 | 0.0% | 0.13% | -29.4% | |
| ALKS | Alkermes plc | $10,816,000 | +26.4% | 250,251 | 0.0% | 0.11% | +25.6% | |
| IDRA | Buy | Idera Pharmaceuticals, Inc. | $10,711,000 | -22.6% | 7,000,977 | +0.2% | 0.11% | -23.3% |
| ADHD | Alcobra Ltd. | $10,490,000 | +18.5% | 2,336,359 | 0.0% | 0.11% | +18.3% | |
| ASND | Buy | Ascendis Pharma A/Ssponsored adr | $9,893,000 | +5.5% | 745,521 | +47.5% | 0.10% | +5.1% |
| MGNX | MacroGenics, Inc. | $9,816,000 | +44.0% | 363,676 | 0.0% | 0.10% | +43.1% | |
| DERM | Buy | Dermira, Inc. | $9,548,000 | +67.9% | 326,428 | +18.7% | 0.10% | +66.7% |
| IMGN | Sell | ImmunoGen, Inc. | $9,287,000 | -75.5% | 3,015,353 | -32.3% | 0.10% | -75.8% |
| MRUS | New | Merus N.V. | $8,972,000 | – | 1,122,859 | +100.0% | 0.09% | – |
| LGND | Ligand Pharmaceuticals Incorporated | $8,753,000 | +11.4% | 73,386 | 0.0% | 0.09% | +10.8% | |
| AGIO | Sell | Agios Pharmaceuticals, Inc. | $8,711,000 | -30.3% | 207,915 | -32.5% | 0.09% | -31.1% |
| ZGNX | Zogenix, Inc. | $8,050,000 | -12.9% | 1,000,000 | 0.0% | 0.08% | -13.4% | |
| DMTX | Dimension Therapeutics, Inc. | $7,511,000 | -23.4% | 1,251,881 | 0.0% | 0.08% | -23.3% | |
| AIMT | Buy | Aimmune Therapeutics, Inc. | $7,292,000 | +115.1% | 673,908 | +169.6% | 0.08% | +111.1% |
| VTAE | Vitae Pharmaceuticals, Inc. | $6,880,000 | +62.8% | 637,597 | 0.0% | 0.07% | +60.0% | |
| SAGE | Sage Therapeutics, Inc. | $6,751,000 | -6.0% | 224,048 | 0.0% | 0.07% | -6.6% | |
| AKTX | Buy | Akari Therapeutics plcsponsored adr | $6,703,000 | +20.9% | 496,901 | +25.5% | 0.07% | +20.7% |
| PRQR | Sell | ProQR Therapeutics N.V. | $5,973,000 | -9.3% | 1,234,095 | -8.6% | 0.06% | -8.7% |
| ALDR | New | Alder BioPharmaceuticals, Inc. | $5,427,000 | – | 217,328 | +100.0% | 0.06% | – |
| RARE | Sell | Ultragenyx Pharmaceutical Inc. | $5,424,000 | -30.9% | 110,894 | -10.5% | 0.06% | -31.3% |
| NTRA | Natera, Inc. | $5,429,000 | +26.7% | 450,000 | 0.0% | 0.06% | +26.7% | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $5,371,000 | +10.4% | 1,009,509 | 0.0% | 0.06% | +9.8% | |
| AERI | Aerie Pharmaceuticals, Inc. | $5,269,000 | +44.8% | 299,356 | 0.0% | 0.06% | +44.7% | |
| CNCE | Sell | Concert Pharmaceuticals, Inc. | $5,279,000 | -22.1% | 470,058 | -5.2% | 0.06% | -22.5% |
| NERV | New | Minerva Neurosciences, Inc. | $5,191,000 | – | 508,405 | +100.0% | 0.05% | – |
| NeuroDerm Ltd. | $4,956,000 | +15.1% | 305,000 | 0.0% | 0.05% | +15.6% | ||
| MDGN | Buy | Medgenics, Inc. | $4,887,000 | +45.2% | 880,539 | +15.1% | 0.05% | +45.7% |
| SYRS | New | Syros Pharmaceuticals, Inc. | $3,711,000 | – | 204,465 | +100.0% | 0.04% | – |
| MCRB | Seres Therapeutics, Inc. | $3,631,000 | +9.4% | 125,000 | 0.0% | 0.04% | +8.6% | |
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $3,637,000 | -43.5% | 5,122,153 | -6.8% | 0.04% | -44.1% |
| ECYT | Sell | Endocyte, Inc. | $3,629,000 | -31.0% | 1,130,577 | -33.3% | 0.04% | -30.9% |
| LOXO | Loxo Oncology, Inc. | $3,193,000 | -15.2% | 137,735 | 0.0% | 0.03% | -17.5% | |
| CRIS | Curis, Inc. | $3,119,000 | -3.1% | 1,999,303 | 0.0% | 0.03% | -2.9% | |
| RXDX | Ignyta, Inc. | $3,095,000 | -19.9% | 571,000 | 0.0% | 0.03% | -22.0% | |
| JUNO | Juno Therapeutics, Inc. | $3,075,000 | +0.9% | 80,000 | 0.0% | 0.03% | 0.0% | |
| TRVN | Trevena, Inc. | $2,835,000 | -23.8% | 450,000 | 0.0% | 0.03% | -23.1% | |
| GLYC | New | GlycoMimetics, Inc. | $2,772,000 | – | 381,235 | +100.0% | 0.03% | – |
| NBRV | Nabriva Therapeutics AGsponsored adr | $2,625,000 | -16.3% | 350,000 | 0.0% | 0.03% | -15.2% | |
| Array BioPharma Inc. Notes 3.0% 6/1/2020note 3.0% 6/1/2020 | $2,544,000 | +6.8% | 3,000,000 | 0.0% | 0.03% | +8.0% | ||
| OSIR | Osiris Therapeutics, Inc. | $2,541,000 | -10.8% | 499,193 | 0.0% | 0.03% | -10.0% | |
| ADMS | Adamas Pharmaceuticals, Inc. | $2,614,000 | +4.7% | 172,630 | 0.0% | 0.03% | +3.8% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $2,437,000 | +1.4% | 4,450,000 | 0.0% | 0.03% | +4.0% | |
| SELB | New | Selecta Biosciences, Inc. | $2,504,000 | – | 178,950 | +100.0% | 0.03% | – |
| EPZM | Epizyme, Inc. | $2,381,000 | -15.5% | 232,481 | 0.0% | 0.02% | -16.7% | |
| PRTO | Proteon Therapeutics, Inc. | $2,398,000 | +3.8% | 298,591 | 0.0% | 0.02% | +4.2% | |
| Protalix BioTherapeutics, Inc. Notes 4.5% 9/15/18note 4.5% 9/15/2018 | $2,300,000 | -1.5% | 3,423,000 | 0.0% | 0.02% | -4.0% | ||
| STML | Stemline Therapeutics, Inc. | $2,258,000 | +45.3% | 333,497 | 0.0% | 0.02% | +50.0% | |
| NVIV | InVivo Therapeutics Holdings Corp. | $2,312,000 | -17.2% | 400,000 | 0.0% | 0.02% | -17.2% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $2,120,000 | +1.8% | 711,499 | 0.0% | 0.02% | 0.0% | |
| AGLE | New | Aeglea BioTherapeutics, Inc. | $1,965,000 | – | 404,230 | +100.0% | 0.02% | – |
| Trillium Therapeutics Inc. | $1,902,000 | -2.9% | 211,792 | 0.0% | 0.02% | -4.8% | ||
| MSTX | Sell | Mast Therapeutics, Inc. | $1,818,000 | +38.9% | 3,868,026 | -19.4% | 0.02% | +35.7% |
| MDWD | MediWound Ltd. | $1,783,000 | -2.2% | 226,000 | 0.0% | 0.02% | 0.0% | |
| OPHT | Ophthotech Corporation | $1,819,000 | +20.7% | 35,649 | 0.0% | 0.02% | +18.8% | |
| QURE | uniQure N.V. | $1,695,000 | -38.0% | 230,000 | 0.0% | 0.02% | -37.9% | |
| AMRN | Amarin Corporation plcsponsored adr new | $1,732,000 | +41.2% | 801,860 | 0.0% | 0.02% | +38.5% | |
| ENTA | Enanta Pharmaceuticals, Inc. | $1,662,000 | -24.9% | 75,357 | 0.0% | 0.02% | -26.1% | |
| CYTR | CytRx Corporation | $1,472,000 | -16.8% | 659,995 | 0.0% | 0.02% | -21.1% | |
| KPTI | Karyopharm Therapeutics Inc. | $1,456,000 | -24.8% | 216,990 | 0.0% | 0.02% | -25.0% | |
| ASMB | Assembly Biosciences, Inc. | $1,388,000 | +10.6% | 250,000 | 0.0% | 0.02% | +15.4% | |
| CLLS | Cellectis S.A.sponsored ads | $1,330,000 | -3.3% | 50,000 | 0.0% | 0.01% | -6.7% | |
| IONS | Ionis Pharmaceuticals, Inc. | $1,331,000 | -42.5% | 57,140 | 0.0% | 0.01% | -41.7% | |
| GWPH | GW Pharmaceuticals plcads | $1,374,000 | +27.0% | 15,000 | 0.0% | 0.01% | +27.3% | |
| IMDZ | Immune Design Corp. | $1,215,000 | -37.2% | 148,937 | 0.0% | 0.01% | -35.0% | |
| DVAX | Dynavax Technologies Corporation | $1,094,000 | -24.2% | 75,000 | 0.0% | 0.01% | -26.7% | |
| TENX | Tenax Therapeutics, Inc. | $1,075,000 | +24.9% | 420,000 | 0.0% | 0.01% | +22.2% | |
| SCYX | New | SCYNEXIS, Inc. | $1,015,000 | – | 467,600 | +100.0% | 0.01% | – |
| XLRN | Acceleron Pharma Inc. | $977,000 | +28.7% | 28,765 | 0.0% | 0.01% | +25.0% | |
| AFMD | Affimed N.V. | $992,000 | -33.7% | 400,000 | 0.0% | 0.01% | -37.5% | |
| PTN | Palatin Technologies, Inc. | $905,000 | -18.2% | 2,050,000 | 0.0% | 0.01% | -25.0% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $815,000 | +0.2% | 100,000 | 0.0% | 0.01% | 0.0% | |
| FPRX | Five Prime Therapeutics, Inc. | $796,000 | +1.8% | 19,247 | 0.0% | 0.01% | 0.0% | |
| ALDX | Aldeyra Therapeutics, Inc. | $808,000 | +35.8% | 142,000 | 0.0% | 0.01% | +33.3% | |
| ABUS | Arbutus Biopharma Corporation | $628,000 | -15.8% | 180,582 | 0.0% | 0.01% | -12.5% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | $629,000 | -11.7% | 11,340 | 0.0% | 0.01% | -12.5% | |
| SNTA | New | Synta Pharmaceuticals Corp. | $526,000 | – | 2,021,728 | +100.0% | 0.01% | – |
| RTTR | Ritter Pharmaceuticals, Inc. | $612,000 | +35.4% | 400,000 | 0.0% | 0.01% | +20.0% | |
| WINT | New | Windtree Therapeutics, Inc. | $492,000 | – | 254,973 | +100.0% | 0.01% | – |
| BDSI | BioDelivery Sciences International, Inc. | $496,000 | -26.8% | 210,021 | 0.0% | 0.01% | -28.6% | |
| CMRX | Chimerix, Inc. | $453,000 | -23.1% | 115,216 | 0.0% | 0.01% | -16.7% | |
| FMI | Foundation Medicine, Inc. | $390,000 | +2.6% | 20,892 | 0.0% | 0.00% | 0.0% | |
| DNAI | ProNAi Therapeutics, Inc. | $398,000 | -70.5% | 200,000 | 0.0% | 0.00% | -71.4% | |
| AKAOQ | Achaogen, Inc. | $379,000 | +37.3% | 100,000 | 0.0% | 0.00% | +33.3% | |
| LJPC | La Jolla Pharmaceutical Company | $220,000 | -23.3% | 13,746 | 0.0% | 0.00% | -33.3% | |
| CCXI | ChemoCentryx, Inc. | $220,000 | +80.3% | 49,064 | 0.0% | 0.00% | +100.0% | |
| CYCCP | Cyclacel Pharmaceuticals, Inc.pfd conv ex 6% | $83,000 | +9.2% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BTXWS | BioTime, Inc.*w exp 10/1/201 | $9,000 | -25.0% | 20,084 | 0.0% | 0.00% | – | |
| Exit | Aptose Biosciences Inc. | $0 | – | -33,397 | -100.0% | -0.00% | – | |
| DSCO | Exit | Discovery Laboratories, Inc. | $0 | – | -254,973 | -100.0% | -0.00% | – |
| IRWD | Exit | Ironwood Pharmaceuticals, Inc. | $0 | – | -169,163 | -100.0% | -0.02% | – |
| LBIO | Exit | Lion Biotechnologies, Inc. | $0 | – | -1,066,285 | -100.0% | -0.06% | – |
| LIFE | Exit | aTyr Pharma, Inc. | $0 | – | -2,137,606 | -100.0% | -0.09% | – |
| GBT | Exit | Global Blood Therapeutics, Inc. | $0 | – | -600,000 | -100.0% | -0.10% | – |
| OMER | Exit | Omeros Corporation | $0 | – | -749,250 | -100.0% | -0.12% | – |
| Exit | Anacor Pharmaceuticals Inc. 2.0% 15 OCT 2021note 2.0% 10/15/2021 | $0 | – | -42,000,000 | -100.0% | -0.80% | – | |
| Exit | Gilead Sciences, Inc. 1.625% 5/1/16note 1.625% 5/1/2016 | $0 | – | -20,944,000 | -100.0% | -0.91% | – | |
| ANAC | Exit | Anacor Pharmaceuticals, Inc. | $0 | – | -5,122,375 | -100.0% | -2.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.